Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vericel's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vericel's regulatory disclosures and financial reporting.
Vericel Corp’s Principal Accounting Officer Jonathan Siegal reported a same-day option exercise and share sale. On June 26, 2026, he exercised 2,500 stock options at $29.82 per share and sold a total of 2,732 common shares at $44.90 per share in open-market transactions.
Following these trades, he holds 886 common shares directly and 6,500 stock options that remain outstanding and exercisable through February 17, 2033. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance.
Vericel Corp’s Chief Financial Officer, Mara Joseph Anthony Jr., reported an open-market sale of 5,000 shares of common stock. The transaction took place on June 26, 2026 at a price of $44.75 per share. Following this sale, he directly holds 16,009 shares of Vericel common stock.
The filing notes that the sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025, indicating it was scheduled in advance rather than timed discretionarily. The reported holdings include shares acquired through Vericel’s 2015 Employee Stock Purchase Plan under Rule 16b-3 exemptions.
Vericel Corp’s Chief Medical Officer, Jonathan Mark Hopper, reported an exercise-and-sell transaction in company stock. On June 26, 2026, he exercised stock options to acquire 10,000 shares of common stock at $29.82 per share and sold 10,000 shares in open-market trades at $45.00 per share in two 5,000-share blocks.
After these transactions, Hopper directly holds 75,753 shares of Vericel common stock and 25,000 remaining stock options with a $29.82 exercise price expiring on February 17, 2033. The sales were carried out under an automatic Rule 10b5-1 trading plan adopted on May 30, 2025, indicating they were pre-scheduled rather than discretionary market-timing trades.
Vericel Corp's Chief Legal Officer Sean C. Flynn exercised stock options and sold shares in a planned transaction. On June 26, 2026, he exercised options to acquire 15,000 shares of common stock at $16.25 per share, then sold 15,000 shares in an open-market transaction at an average price of $45.64 per share. The sales were made under an automatic Rule 10b5-1 trading plan adopted on December 2, 2025. After these transactions, he directly held 1,647 shares of Vericel common stock.
Vericel Corporation notice: 15,000 shares of Common Stock were sold through a Stock Option Exercise on 06/26/2026. The transaction lists Fidelity Brokerage Services LLC and an aggregate figure of $684,659.03. The filing also shows a prior sale of 15,000 shares by Sean C. Flynn on 06/18/2026 with an aggregate figure of $603,148.50.
VCEL affiliate reported proposed and recent sales of Common Stock via Form 144. The filing lists a proposed sale of 5,000 shares and shows that Joseph A. Mara sold 5,000 shares on 05/07/2026 for $202,500.
The notice also lists restricted stock vesting entries of 1,613, 3,175, and 212 shares (dated 02/18/2023, 02/17/2025, and 02/18/2025) labeled as Compensation.
Notice of proposed resale of Common Stock and recent insider sales. The filing lists proposed sales tied to a 02/18/2026 restricted stock vesting of 232 shares and a 06/26/2026 stock option exercise of 2,500 shares (cash). It also reports two recent dispositions by Jonathan D. Siegal: 3,433 shares sold on 05/06/2026 for $130,454 and 1,422 shares sold on 05/07/2026 for $57,591.
VCEL submitted a Form 144 disclosing the sale of 10,000 shares of Common Stock via a stock option exercise reported on 06/26/2026. The filing also lists prior dispositions by Jonathan M. Hopper: 3,472 shares on 04/02/2026 for $121,520 and 4,375 shares on 06/02/2026 for $153,125.
Vericel Corp Chief Operating Officer Michael Halpin reported an exercise-and-sale transaction in company stock. On June 18, 2026, he exercised options to acquire 10,000 shares of common stock at $16.66 per share and then sold 10,000 shares in an open-market transaction at $40.24 per share.
The filing notes that the sales were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025, indicating the timing was set in advance. Following these transactions, Halpin directly holds 16,248 shares of Vericel common stock.
Vericel Corp Chief Legal Officer Sean C. Flynn exercised options to acquire 15,000 shares of common stock at $16.25 per share and, on the same day, sold 15,000 shares at an average price of $40.21 per share. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025, indicating it was scheduled in advance. After these transactions, Flynn holds 1,647 common shares directly and 70,000 stock options exercisable at $16.25 per share that are scheduled to expire on November 4, 2029.